After CVS' Solid Quarter, Focus Is on Aetna Acquisition
We expect the combined company will fundamentally change how healthcare is provided to individuals.
We are reiterating our $99 fair value estimate for CVS Health (CVS) after the wide-moat pharmacy benefit manager reported strong first-quarter results. The company reported a robust increase in revenue for all segments as its efforts to become a preferred pharmacy in restricted networks drove the retail top line and a good gain in client wins and client member growth bolstered its PBM operations. Impressively, CVS also expanded its gross and operating margins by 25 and 23 basis points, respectively. The company’s retail segment did experience a 42-basis-point decrease in gross margin as it was forced to discount its generic pharmaceutical products in order to obtain preferred pharmacy status on several PBM pharmacy networks. However, the company was able to offset this headwind with a 96-basis-point reduction in centralized costs, driving overall operating margin for the segment up 54 basis points. We believe management did a great job driving profits and recovering its top line over the quarter, but the main focus for investors moving forward will be the acquisition of Aetna (AET).
Management said the merger is on track and expected to close by the end of 2018. CVS has established an integration team, realigned its operations to make the transition easier, and issued acquisition-related bonds to lock in a low cost of debt. Aetna reported that it has also reorganized its own operations by combining all healthcare operations and selling its nonhealthcare businesses. In addition, the managed-care organization acquired 279,000 new Medicare members as it looks to build its portfolio in one of the fastest-growing and most consistent health insurance cohorts. This development falls in line with what the management teams of both CVS and Aetna said was their stated operational goal for the new healthcare services company. We believe this preparation well ahead of the transaction closing is a positive, as it should lessen any major integration issues between the two complex companies.
Vishnu Lekraj does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.